Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications (Q38010747)

26 August 2017

Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications (English)

1 reference

26 August 2017

1 reference

6

Rafael Rosell

1 reference

26 August 2017

Clara Mayo

1

1 reference

26 August 2017

Jordi Bertran-Alamillo

2

1 reference

26 August 2017

Miguel Ángel Molina-Vila

3

1 reference

26 August 2017

Ana Giménez-Capitán

4

1 reference

26 August 2017

Carlota Costa

5

1 reference

26 August 2017

1 May 2012

1 reference

26 August 2017

1 reference

26 August 2017

13

1 reference

26 August 2017

7

1 reference

26 August 2017

789-802

1 reference

26 August 2017

Cancer statistics, 2008

1 reference

Personalized medicine and inhibition of EGFR signaling in lung cancer

21 January 2018

1 reference

New driver mutations in non-small-cell lung cancer

21 January 2018

1 reference

Treatment of non-small-cell lung cancer with erlotinib or gefitinib

21 January 2018

1 reference

Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers

21 January 2018

1 reference

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

21 January 2018

1 reference

Acquired resistance to tyrosine kinase inhibitors during cancer therapy

21 January 2018

1 reference

Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.

21 January 2018

1 reference

FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.

21 January 2018

1 reference

BRCA1: a new genomic marker for non-small-cell lung cancer

21 January 2018

1 reference

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

Structure and clinical relevance of the epidermal growth factor receptor in human cancer

21 January 2018

1 reference

EGFR antagonists in cancer treatment

21 January 2018

1 reference

Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer

21 January 2018

1 reference

Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops

21 January 2018

1 reference

Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails

21 January 2018

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

Biological and clinical implications of EGFR mutations in lung cancer.

21 January 2018

1 reference

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

21 January 2018

1 reference

Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480.

21 January 2018

1 reference

Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer

21 January 2018

1 reference

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan

21 January 2018

1 reference

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

21 January 2018

1 reference

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

Epidermal growth factor receptor (EGFR) signaling in cancer

21 January 2018

1 reference

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 January 2018

1 reference

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial

21 January 2018

1 reference

Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study

21 January 2018

1 reference

Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer

21 January 2018

1 reference

Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer.

21 January 2018

1 reference

Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer

21 January 2018

1 reference

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

21 January 2018

1 reference

Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors

21 January 2018

1 reference

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

21 January 2018

1 reference

Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer

21 January 2018

1 reference

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay

21 January 2018

1 reference

Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations.

21 January 2018

1 reference

Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

21 January 2018

1 reference

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

21 January 2018

1 reference

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients

21 January 2018

1 reference

Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib

21 January 2018

1 reference

TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

21 January 2018

1 reference

Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.

21 January 2018

1 reference

Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling

21 January 2018

1 reference

Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.

21 January 2018

1 reference

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

21 January 2018

1 reference

Epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors

21 January 2018

1 reference

Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation

21 January 2018

1 reference

Detection of mutations in EGFR in circulating lung-cancer cells

21 January 2018

1 reference

Germ-line and somatic presentations of the EGFR T790M mutation in lung cancer

21 January 2018

1 reference

Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.

21 January 2018

1 reference

Novel therapeutic targets in non-small cell lung cancer

21 January 2018

1 reference

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

21 January 2018

1 reference

Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling

21 January 2018

1 reference

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

21 January 2018

1 reference

EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases

21 January 2018

1 reference

Regulation of DNA double-strand break repair pathway choice

21 January 2018

1 reference

BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer

21 January 2018

1 reference

Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression

21 January 2018

1 reference

Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130.

21 January 2018

1 reference

Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling

21 January 2018

1 reference

mRNA expression levels and genetic status of genes involved in the EGFR and NF-κB pathways in metastatic non-small-cell lung cancer patients

21 January 2018

1 reference

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

21 January 2018

1 reference

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

21 January 2018

1 reference

Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance

21 January 2018

1 reference

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/PGS.12.54

1 reference

26 August 2017

1 reference